Local immunotherapy improves immune response in ovarian cancer
Project 2: Local immunotherapy corrects chemokine patterns in ovarian cancer
['FUNDING_P01'] · ROSWELL PARK CANCER INSTITUTE CORP · NIH-10916166
This study is testing a new way to boost the immune system in ovarian cancer patients by using a mix of treatments that help bring more cancer-fighting immune cells to the tumor while reducing the ones that hold the immune response back, and it’s designed for those receiving a specific vaccine and chemotherapy.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROSWELL PARK CANCER INSTITUTE CORP (nih funded) |
| Locations | 1 site (BUFFALO, UNITED STATES) |
| Trial ID | NIH-10916166 on ClinicalTrials.gov |
What this research studies
This research investigates a new approach to enhance the immune response in ovarian cancer patients by using a combination of therapies that attract specific immune cells to the tumor site. The treatment involves administering a combination of rintatolimod, IFNα, and celecoxib directly into the abdominal cavity, aiming to increase the presence of tumor-fighting immune cells while reducing those that suppress the immune response. The study is currently in a phase I/II trial to assess the safety and effectiveness of this local immunotherapy in patients receiving a specific vaccine alongside chemotherapy. Patients will be monitored for immune cell accumulation and overall treatment response.
Who could benefit from this research
Good fit: Ideal candidates for this research are ovarian cancer patients who are undergoing neoadjuvant chemotherapy and are eligible for vaccination with the αDC1 vaccine.
Not a fit: Patients with advanced ovarian cancer who are not candidates for the αDC1 vaccine or those who have already received extensive prior treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for ovarian cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promising results with similar immunotherapy approaches in other cancers, indicating potential for success in this novel application for ovarian cancer.
Where this research is happening
BUFFALO, UNITED STATES
- ROSWELL PARK CANCER INSTITUTE CORP — BUFFALO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KALINSKI, PAWEL — ROSWELL PARK CANCER INSTITUTE CORP
- Study coordinator: KALINSKI, PAWEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.